1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow IMA203: new trials by email Literature Review of IMA203 trials Research Report on IMA203
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant, Mucosal Melanoma | Phase 3 | Recruiting | Immatics US, Inc. | 450 | 2025-01-14 | 2026-10-30 |
Melanoma, Cutaneous Malignant (1)
Canada (1) · France (1) · Germany (1) · Netherlands (1) · United Kingdom (1) · United States (1)